Percheron Advances HMBD-002 into Innovative Phase II After Positive Phase I Cancer Data

Percheron Therapeutics ( (AU:PER) ) has shared an update.

Percheron Therapeutics has reported final data from a completed phase I clinical trial of its lead candidate HMBD-002, showing a favourable safety profile with few severe treatment-related adverse events and early signs of anti-tumour activity, including tumour shrinkage and prolonged stable disease in heavily pre-treated metastatic cancer patients. Building on these results, the company has released the design of an adaptive, modular phase II trial that will test HMBD-002 across several tumour types, starting with triple-negative breast cancer, EGFR‑mutant non-small-cell lung cancer, HER2‑negative oesophageal cancer and endometrial cancer, aiming to generate frequent data read-outs while managing risk across multiple study arms; manufacturing of new drug substance for phase II is underway and remains the responsibility of licensor Hummingbird Bioscience, supporting Percheron’s capital-efficient progression into the next stage of clinical development.

The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases. Listed on the ASX, FSE and US OTC markets, the company is advancing its lead asset HMBD-002, an antibody-based cancer therapy licensed from Hummingbird Bioscience, targeting difficult-to-treat tumour types in collaboration with leading global cancer centres.

Average Trading Volume: 6,815,869

Technical Sentiment Signal: Sell

Current Market Cap: A$9.79M

Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.